AnaptysBio Inc (NAS:ANAB)

$ 24.9 0.96 (4.01%) Market Cap: 680.23 Mil Enterprise Value: 342.96 Mil PE Ratio: 0 PB Ratio: 14.24 GF Score: 62/100

AnaptysBio Inc to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event Transcript
Oct 25, 2023
AnaptysBio Inc To virtual BTLA Agonist (ANB032) R&D Event Transcript
May 25, 2023
AnaptysBio Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
AnaptysBio Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
AnaptysBio Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 17, 2020
AnaptysBio Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
AnaptysBio Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019

AnaptysBio Inc at Jefferies Virtual London Healthcare Conference Transcript

Nov 17, 2020 / 05:35PM GMT

Release Date Price: $26.63 (-2.88%)

Transcript

Biren N. Amin

Jefferies LLC, Research Division - MD and Senior Equity Research Analyst

Welcome, everyone. This is Biren Amin, biotech analyst here at Jefferies. I'd like to welcome everyone to the Jefferies Virtual Healthcare Conference.

We have our next company, AnaptysBio, presenting and their CEO, Hamza Suria. So Hamza, please take it away.

Hamza Suria

AnaptysBio, Inc. - President, CEO & Director

Thanks, Biren. Appreciate the intro, and thank you to the Jefferies team for giving us an opportunity to provide an update on AnaptysBio. As Biren mentioned, my name is Hamza Suria. I'm the President and CEO of AnaptysBio.

I will be making forward-looking statements today. We encourage you to review our SEC filings for relevant disclosures and risks.

AnaptysBio is an antibody R&D engine focused on first-in-class immunology opportunities. We have a deep, wholly owned clinical pipeline with multiple catalysts up over the upcoming quarters, including an end-of-Phase II meeting, including Phase II data, Phase I data and the new

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.